Abbreviations
Fi02, fraction of oxygen in inspired air FXII, Hageman factor HK, high molecular weight kininogen RDS, respiratory distress syndrome Paoe oxygen tension in arterial blood proteins that interact in a complicated way. When activated, the contact factors plasma prekallikrein, FXII, and factor XI are converted to serine proteases that are capable of activating the complement, fibrinolytic, coagulation, and kallikrein-kinin systems (7) (8) (9) . Inhibitors regulate and control the activation of the cascades. C1-inhibitor is the most important inhibitor of the contact system (10) . It exerts its regulatory role by inhibiting activated FXII, FXII fragment, and plasma kallikrein (10) . In addition, az-macroglobulin and a,-protease inhibitor inhibit plasma kallikrein (1 1) and factor XIa (l2), respectively. Contact activation initiates other proteolytic plasma cascades. Plasma prekallikrein, activated FXII, and factor XIa may convert the proenzyme plasminogen to plasmin (1 3, 14) .
When the plasma kallikrein-kinin system is activated, HK is cleaved proteolytically and three characteristic bands are identified by electrophoresis followed by immunoblotting. The relative amount of each of these bands gives an indication of the degree of plasma kallikrein-kinin activation. Band I with molecular mass of 149 000 D represents the native form of HK; band I1 (molecular mass 104 000 D) and band 111 (molecular mass 99 000 D) are considered to represent degradation products of kininogen. The relative amounts of these two compounds are therefore of special interest when considering the rate of proteolytic cleavage of kininogen ( 15) .
The plasma kallikrein-kinin system may play a fundamental role in the development of shock-like conditions because its activation results in the formation of the very potent vasodilatator bradykinin, which increases capillary permeability as well (7, 9, 16, 17) . We have previously shown that preterm babies with RDS have low plasma prekallikrein and kallikrein inhibition levels, indicating that the plasma kallikrein-kinin system might be activated in this condition (6) .
The purpose of the present study was to investigate more specifically whether or not the plasma kallikrein-kinin system is activated in RDS. In addition to components of the plasma kallikrein-kinin system including HK and its degradation products, we have also determined components of the fibrinolytic system and antithrombin 111 in preterm babies with and without RDS. Additionally, we have studied whether rescue treatment with a single dose of porcine surfactant influences the activation of these systems.
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babies received one dose of natural surfactant as rescue treat-of the babies. Statistical differences between the groups were ment. Mean gestational age in this group of patients was 28.5 tested by a two-tailed l test. A p value < 0.05 was considered (SD 0.8) wk and birth weight was 1 241 (SD 134) g. Group 2 statistically significant. babies were not treated with surfactant. They had a mean gestational age of 28.8 (SD 3.2) wk and birth weight of 1 197 (SD 349) g.
RESULTS
The babies with RDS fulfilled the criteria for entering the first Collaborative European Multicenter Trial of replacement therapy with porcine surfactant (Curosurf) (19) . The protocol and results from this study have previously been published in detail (19) . In that study, RDS babies were randomized either to receive or not to receive a single dose of surfactant. Group 3 (n = 9) consisted of controls without RDS or any other significant respiratory problems. To be enrolled as controls, the babies did not have an oxygen requirement 20.30 for more than I h after birth and required artificial ventilation only for stabilization during the first 2 d after birth. They had a mean gestational age of 28.9 (SD 1.8) wk and birth weight of 1 138 (SD 207) g. The mothers of three of them received dexamethasone between 1 and 7 d before giving birth. Eight of nine control babies were delivered by cesarean section. Their mean 1-min Apgar score was 6.7 (range 2-9), and the 5-min score was 8.4 (range 6-10). Four of these babies required intermittent positive ventilation of duration ranging between 1 and 36 h postpartum.
There were no significant differences between the three groups with regard to birth weight and gestational age. All babies were larger than the 2.5 percentile for weight.
Procedure. An arterial or venous umbilical catheter was inserted for clinical monitoring; the routine in our unit is to remove such indwelling catheters within 96 h if the babies do not require artificial ventilation.
All the RDS babies had indwelling arterial umbilical catheters, which were removed at latest approximately 24 h after extubation. Blood for analysis was withdrawn as soon as possible after stabilization after birth. The first blood sample (d 1) was withdrawn before the age of 12 h at a mean age of 7.5 (SD 3.0) h and then at 24-h intervals as long as an umbilical catheter remained in position. For babies receiving surfactant, the first blood sample was withdrawn 5 min before surfactant was given. All three groups were treated identically with regard to timing of blood sampling.
Catheters in control babies were removed between 72 and 96 h of age and data are therefore given only until d 4 after birth.
From the catheter, 0.9 mL of blood was withdrawn, avoiding contact with any heparin, and put into soft plastic tubes with 0.1 mL 3.2% citrate. After centrifugation, plasma was sucked off and frozen at -20°C until assayed.
Measuremenls. Plasma kallikrein activity, prekallikrein, and functional kallikrein inhibition values were determined with the chromogenic peptide substrate S-2302 (Kabi, Stockholm, Sweden) using an automated enzyme analyzer (Cobas Bio, Hoffmann La Roche, Basel, Switzerland) as previously described (20) . The chromogenic substrate S-2251 (Kabi) was used to determine plasminogen, plasmin and antiplasmin values. The values of prekallikrein, kallikrein inhibition, plasminogen, and antiplasmin are given as percentages of standard plasma pool values. Antithrombin I11 values were assayed with the chromogenic substrate S-2238 (Kabi) as previously described (20) . Plasma total protein was measured with a routine technique (2 1).
HK and its degradation products were determined by SDS PAGE followed by immunoblotting according to standard procedures (22, 23) . The blot was washed, quenched, and incubated with rabbit antiserum against human HK. Bound antibodies were finally detected with alkaline phosphatase-conjugated goat antibodies against rabbit IgG. The developed immunoblots were scanned and the area under the curve for each band was used as a measure of the relative amount of native kininogen or degradation product (24) .
The project was approved by the ethical committee of the hospital, and informed consent was obtained from the parents Figure 5 shows a SDS-PAGE immunoblot of HK and its degradation products in one RDS patient treated with surfactant the first week after birth. Band 111, which is the most important indicator of HK proteolysis, was clearly present at d 1. After d 5 it disappeared completely. Table I . There range.
were no differences between the three groups except with regard found.
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Plasma kallikrein inhibition values increased in all the three groups during the study period (Fig. 3 ). There were no differences between groups 1 and 2 throughout the observation period. Group 1 babies had, however, signficantly lower values than controls at d 2 ( p < 0.02) and 4 ( p < 0.05), whereas group 2 f 2 3 4 5 6 7
patients had values not significantly different from controls. (7) 15 (9) 22 (17) to plasma antiplasmin values, which at d 2 were significantly lower in the group 2 RDS babies than in controls.
Antithrombin 111 values were low compared to pool plasma values from normal adults, but there was neither any difference between the groups nor any significant change during the study (data not shown).
Plasma total protein. 
DISCUSSION
In the present study, we have demonstrated that plasma prekallikrein values were significantly lower in babies with severe RDS compared with control babies without RDS the first days after birth. These data are basically in accordance with our previous findings (6) . During the first day of life, mean plasma prekallikrein in both groups of RDS patients was 63% of the values found in premature control patients without RDS. Although the plasma total protein was decreased in RDS babies as well, this reduction was, in mean, only 11% compared with control values. The differences in prekallikrein values found between the groups in this study is therefore probably not due to a general decreased protein synthesis in the liver in RDS babies. On the contrary, the data indicate that the plasma kallikreinkinin system is activated in RDS.
The low HK levels found at d 1 in RDS patients, together with the rapid decrease in the amount of its degradation products (band 111) from d I to d 2, as found in this study, represent the first direct proof that the plasma kallikrein-kinin system is activated in RDS. Rescue treatment with porcine surfactant does not seem to enforce or prevent this activation or influence the fibrinolytic system either. Whether or not prophylactic surfactant treatment inhibits activation of the plasma kallikrein-kinin system is not known and should be worthwhile to investigate.
Judging by plasminogen values and plasmin activity, the fibrinolytic system is not activated in RDS, in contrast to findings by Suzuki (25) .
It has been previously demonstrated that plasma prekallikrein is transformed to kallikrein in a series of other pathophysiologic conditions such as septicemia, multitraumatized patients with multiple organ failure, and the adult RDS (1) (2) (3) (4) (5) 17) . On the basis of the present data it may therefore be tempting to speculate that RDS has some features in common with "posttraumatic" diseases such as those listed above (1) (2) (3) (4) (5) . It is known that RDS may be aggravated and precipitated by shock, hypothermia, and acidosis (26, 27) . To what extent activation of the plasma kallikrein-kinin system influences the clinical development in patients with RDS is, however, uncertain.
In conclusion, we have found lowered plasma prekallikrein and kallikrein inhibition values in babies with RDS. The first day after birth, the total amount of HK is reduced in these patients compared with premature babies not having RDS. Furthermore, the rate of proteolytic degradation of HK is reduced in RDS babies from the first to the second day of life. We have therefore documented that the kallikrein-kinin system is activated in RDS. Rescue treatment with one dose of natural porcine surfactant does not seem to influence such an activation.
